It targets key pathways involved in CRC progression including angiogenesis via inhibition of VEGFR1, VEGFR2, VEGFR3, TIE2, PDGFR, FGFR1, and FGFR2; proliferation via inhibition of c-KIT, RAF1, BRAF, and RET; and metastasis via inhibition of VEGFR2, VEGFR3, and PDGFR (Arai et al., 2019). This evidence concerns the gene FLT4 and colorectal carcinoma.